302 related articles for article (PubMed ID: 26823490)
1. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
Weekes CD; Lamberts LE; Borad MJ; Voortman J; McWilliams RR; Diamond JR; de Vries EG; Verheul HM; Lieu CH; Kim GP; Wang Y; Scales SJ; Samineni D; Brunstein F; Choi Y; Maslyar DJ; Colon-Otero G
Mol Cancer Ther; 2016 Mar; 15(3):439-47. PubMed ID: 26823490
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
Liu JF; Moore KN; Birrer MJ; Berlin S; Matulonis UA; Infante JR; Wolpin B; Poon KA; Firestein R; Xu J; Kahn R; Wang Y; Wood K; Darbonne WC; Lackner MR; Kelley SK; Lu X; Choi YJ; Maslyar D; Humke EW; Burris HA
Ann Oncol; 2016 Nov; 27(11):2124-2130. PubMed ID: 27793850
[TBL] [Abstract][Full Text] [Related]
3. Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
Gerber DE; Infante JR; Gordon MS; Goldberg SB; Martín M; Felip E; Martinez Garcia M; Schiller JH; Spigel DR; Cordova J; Westcott V; Wang Y; Shames DS; Choi Y; Kahn R; Dere RC; Samineni D; Xu J; Lin K; Wood K; Royer-Joo S; Lemahieu V; Schuth E; Vaze A; Maslyar D; Humke EW; Burris HA
Clin Cancer Res; 2020 Jan; 26(2):364-372. PubMed ID: 31540980
[TBL] [Abstract][Full Text] [Related]
4. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
Lamberts LE; Menke-van der Houven van Oordt CW; ter Weele EJ; Bensch F; Smeenk MM; Voortman J; Hoekstra OS; Williams SP; Fine BM; Maslyar D; de Jong JR; Gietema JA; Schröder CP; Bongaerts AH; Lub-de Hooge MN; Verheul HM; Sanabria Bohorquez SM; Glaudemans AW; de Vries EG
Clin Cancer Res; 2016 Apr; 22(7):1642-52. PubMed ID: 26589435
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET.
Terwisscha van Scheltinga AG; Ogasawara A; Pacheco G; Vanderbilt AN; Tinianow JN; Gupta N; Li D; Firestein R; Marik J; Scales SJ; Williams SP
Mol Cancer Ther; 2017 Jan; 16(1):134-142. PubMed ID: 27760836
[TBL] [Abstract][Full Text] [Related]
6. An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
Liu J; Burris H; Wang JS; Barroilhet L; Gutierrez M; Wang Y; Vaze A; Commerford R; Royer-Joo S; Choeurng V; Humke E; Moore K
Gynecol Oncol; 2021 Dec; 163(3):473-480. PubMed ID: 34627611
[TBL] [Abstract][Full Text] [Related]
7. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Santin AD; Vergote I; González-Martín A; Moore K; Oaknin A; Romero I; Diab S; Copeland LJ; Monk BJ; Coleman RL; Herzog TJ; Siegel J; Kasten L; Schlicker A; Schulz A; Köchert K; Walter AO; Childs BH; Elbi C; Bulat I
Int J Gynecol Cancer; 2023 Apr; 33(4):562-570. PubMed ID: 36564099
[TBL] [Abstract][Full Text] [Related]
8. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Perez RP; Bauer TM; Ruiz-Soto R; Birrer MJ
J Clin Oncol; 2017 Apr; 35(10):1112-1118. PubMed ID: 28029313
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.
Danila DC; Szmulewitz RZ; Vaishampayan U; Higano CS; Baron AD; Gilbert HN; Brunstein F; Milojic-Blair M; Wang B; Kabbarah O; Mamounas M; Fine BM; Maslyar DJ; Ungewickell A; Scher HI
J Clin Oncol; 2019 Dec; 37(36):3518-3527. PubMed ID: 31689155
[TBL] [Abstract][Full Text] [Related]
10. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
[TBL] [Abstract][Full Text] [Related]
11. Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
Hamilton E; O'Malley DM; O'Cearbhaill R; Cristea M; Fleming GF; Tariq B; Fong A; French D; Rossi M; Brickman D; Moore K
Gynecol Oncol; 2020 Sep; 158(3):640-645. PubMed ID: 32513564
[TBL] [Abstract][Full Text] [Related]
12. First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
Maitland ML; Sachdev JC; Sharma MR; Moreno V; Boni V; Kummar S; Stringer-Reasor E; Lakhani N; Moreau AR; Xuan D; Li R; Powell EL; Jackson-Fisher A; Bowers M; Alekar S; Xin X; Tolcher AW; Calvo E
Clin Cancer Res; 2021 Aug; 27(16):4511-4520. PubMed ID: 34083232
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma.
Sandhu S; McNeil CM; LoRusso P; Patel MR; Kabbarah O; Li C; Sanabria S; Flanagan WM; Yeh RF; Brunstein F; Nazzal D; Hicks R; Lemahieu V; Meng R; Hamid O; Infante JR
Invest New Drugs; 2020 Jun; 38(3):844-854. PubMed ID: 31385109
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.
Moore KN; Borghaei H; O'Malley DM; Jeong W; Seward SM; Bauer TM; Perez RP; Matulonis UA; Running KL; Zhang X; Ponte JF; Ruiz-Soto R; Birrer MJ
Cancer; 2017 Aug; 123(16):3080-3087. PubMed ID: 28440955
[TBL] [Abstract][Full Text] [Related]
15. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Banerjee S; Oza AM; Birrer MJ; Hamilton EP; Hasan J; Leary A; Moore KN; Mackowiak-Matejczyk B; Pikiel J; Ray-Coquard I; Trask P; Lin K; Schuth E; Vaze A; Choi Y; Marsters JC; Maslyar DJ; Lemahieu V; Wang Y; Humke EW; Liu JF
Ann Oncol; 2018 Apr; 29(4):917-923. PubMed ID: 29401246
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors.
Tolaney SM; Do KT; Eder JP; LoRusso PM; Weekes CD; Chandarlapaty S; Chang CW; Chen SC; Nazzal D; Schuth E; Brunstein F; Carrasco-Triguero M; Darbonne WC; Giltnane JM; Flanagan WM; Commerford SR; Ungewickell A; Shapiro GI; Modi S
Clin Cancer Res; 2020 Nov; 26(21):5588-5597. PubMed ID: 32694157
[TBL] [Abstract][Full Text] [Related]
17. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM; Pietanza MC; Bauer TM; Ready N; Morgensztern D; Glisson BS; Byers LA; Johnson ML; Burris HA; Robert F; Han TH; Bheddah S; Theiss N; Watson S; Mathur D; Vennapusa B; Zayed H; Lally S; Strickland DK; Govindan R; Dylla SJ; Peng SL; Spigel DR;
Lancet Oncol; 2017 Jan; 18(1):42-51. PubMed ID: 27932068
[TBL] [Abstract][Full Text] [Related]
18. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
[TBL] [Abstract][Full Text] [Related]
19. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.
Stewart AK; Krishnan AY; Singhal S; Boccia RV; Patel MR; Niesvizky R; Chanan-Khan AA; Ailawadhi S; Brumm J; Mundt KE; Hong K; McBride J; Shon-Nguyen Q; Xiao Y; Ramakrishnan V; Polson AG; Samineni D; Leipold D; Humke EW; McClellan JS; Berdeja JG
Blood Cancer J; 2019 Feb; 9(2):17. PubMed ID: 30718503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]